Pentraxin-3 is a PI3K signaling target that promotes stem cell–like traits in basal-like breast cancers
Clémence Thomas(Beth Israel Deaconess Medical Center), Antoine E. Karnoub(Broad Institute), Anne Vincent‐Salomon(Université Paris Sciences et Lettres), Vanessa Benhamo(Institut Curie), Whitney S. Henry(Whitehead Institute for Biomedical Research), Anthony Y. Collmann(Beth Israel Deaconess Medical Center), Benjamin Cuiffo(Beth Israel Deaconess Medical Center), Elisabetta Marangoni(Université Paris Sciences et Lettres), Charles M. Perou(Segeberger Kliniken), Laetitia Fuhrmann(Institut Curie), Alex Toker(Beth Israel Deaconess Medical Center), Manoj Bhasin(Georgia Institute of Technology), Cheng Fan(University of North Carolina at Chapel Hill), Albert S. Baldwin(Unknown)
Cited by 52
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
The molecular portraits of breast tumors are conserved across microarray platforms
|BMC Genomics|2006|1.5k